- I am still wondering why none of the major market players for viral conjunctivitis have collaborated with Starpharma to bring the formulation into clinical trials
Cheryl use to work for Novartis
Maybe she could sew up a deal with them
Major companies in Viral Conjunctivitis Drugs Market are:
- Adenovir Pharma.
- Allergan.
- NanoViricides.
- Shire.
- NovaBay Pharmaceuticals.
- Novartis.
- Panoptes Pharma.
- NicOx.
15 Apr 2024
SPL7013 has been ready to go into the clinic since 2016
Over the years Starpharma has been talking about "Pink Eye" or Viral Conjunctivitis.
Conjunctivitis also known as pink eye is inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid. The most common infectious causes are viral, followed by bacterial infections.In the majority of viral cases there is no specific treatment. Most cases due to bacterial infection will resolve without treatment, however antibiotics can shorten the illness
in adult viral causes are most common while in children bacterial causes are more common
Viral conjunctivitis can be brought on by infections of upper respiratory tract, a cold, sore throat,Herpes simplex virus (cold sores), genital herpes, and varicella zoster (chickenpox, shingles)
The most common form of viral conjunctivitis is adenovirus. It is highly contagious
Conjunctivitis is caused by
viral infection
bacterial infections (staphylococci - found in the skin and mucous membranes, streptococci - found in mouth, skin, intestines, upper respiratory tract, and chlamydia trachomatis
allergies - such as pollen, perfume, cosmetics, smoke, dust mites, excetra excetra
There are many side effects related to the treatment of viral conjunctivitis with current available drug Codofovir. It is taken intravenously and must be combined with another drug Probenecid
Side effects of Codofovir
Neurotoxicity (kidney damage), nausea, vomiting, neutropenia, hair loss, weakness, head aches, chills, and decreased intraocular pressure
Starpharma's formulation is topical, has no side effects and is applied directly to eye.
This web site will show you how to apply cream, gel to eye
http://www.safemedication.com/safem...dminister/HowtoUseEyeOintmentsandGelsProperly
For those that do not understand my comments , below is a link to conjunctivitis
http://www.msdmanuals.com/en-au/hom...d-scleral-disorders/infectious-conjunctivitis
It has been almost 8 years since Starpharma said it's formulation SPL7013 (the active in VivaGel®
has the potential to be a first-in-class anti-viral agent for viral conjunctivitis.
http://www.starpharma.com/news/159
I thought the article below was interesting. Worth a read
https://health.clevelandclinic.org/itchy-red-eyes-how-to-tell-if-its-allergy-or-infection/
- Anyone remember this picture
- Conjunctivitis Drugs Market Reach Around USD 1.08 Billion – Outlook Till 2023
SPL7013 ophthalmic drops – a potential, novel therapy for adenoviral conjunctivitis
No approved therapies for viral conjunctivitis - remains a significant unmet medical need globally
Viral conjunctivitis affects about 6 million people in the US annually and ~4 million in Europe
Market estimated at US$700 annually
SPL7013 ophthalmic drops: showed potent anti-viralactivity against multiple ophthalmic pathogens
significantly decreased duration of shedding (infectivity)
significantly decreased viral replication (efficacy)
are non-irritating
are covered by a US patent (to grant on 11 Dec 2018)
SPL7013 Ophthalmics
SPL7013 is being used to treat viral conjunctivitis. Starpharma has developed an eye drop which is unique. There are currently no approved therapies and our company has the potential answer. I am sure this will be developed externally with partners bearing all costs through clinical trials to market. It may even be purchased outright. Just have to look at the comments made by a study conducted in USA (taken directly from the slides in report). We could have a market winner here
2018 AGM slide regarding SPL7013 and viral conjunctivitis
“Treating viral conjunctivitis is a problem. There's no prescribed treatment for viral conjunctivitis - it's all conservative management.” - PHYSICIAN
“… if you can reduce the infectivity then that would be very beneficial.” - OPHTHALMOLOGIST
“The goal of treatment is limiting the spread of the disease.” - PAEDIATRICIAN
“We really need something that is not irritating for the eye.” - PHYSICIAN
Clinicians felt that SPL7013 “addresses a major unmet need” for Viral Conjunctivitis
Clinicians described its novel mechanism of action as “compelling”
Clinicians were impressed by its ability to inhibit spread of disease
“I would probably prescribe this [SPL7013 ophthalmic drops] for the majority of viral conjunctivitis cases. There's just nothing but positives in this.” - PHYSICIAN
“Wow, I love what I see. This [SPL7013 ophthalmic drops] is a big unmet need. We have nothing for VC so if this came to market you'd have something.” - PHYSICIAN
“If I thought they had viral conjunctivitis I'd use this [SPL7013 ophthalmic drops] on 100% of patients.” - PHYSICIAN
The above are results and verbatim quotes from independent US market research conducted with 18 Physicians/Ophthalmologists/Payers during Sep 2018.
(20min delay)
